

Aubagne, February 17, 2023

## Sartorius Stedim Biotech releases Universal Registration Document 2022

Sartorius Stedim Biotech, a leading partner of the biopharma industry, has released its Universal Registration Document 2022 including the Annual Financial Report today. The document is available under the following link: <https://ir-reports.sartorius.com/en/ssb/fy-2022>.

### Financial calendar

March 27, 2023	Annual Shareholders' Meeting
April 20, 2023	Publication of first-quarter figures (January to March 2023)
July 21, 2023	Publication of first-half figures (January to June 2023)
October 19, 2023	Publication of nine-month figures (January to September 2023)

### A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically. Headquartered in Aubagne, France, the shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In 2022, the company employed roughly 12,000 people, and earned sales revenue of around 3.5 billion euros.

### Contact

Philipp Grontzki  
Head of External Communications  
+49 (0)551.308.5581  
[philipp.grontzki@sartorius.com](mailto:philipp.grontzki@sartorius.com)

Follow Sartorius Stedim Biotech on Twitter [@Sartorius\\_Group](https://twitter.com/Sartorius_Group) and on [LinkedIn](https://www.linkedin.com/company/sartorius).